share_log

Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Thursday, July 18, 2024

Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Thursday, July 18, 2024

champions oncology 将于2024年7月18日星期四宣布第四季度和年度财务结果。
Accesswire ·  07/11 16:05

HACKENSACK, NJ / ACCESSWIRE / July 11, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the fourth quarter and year-ended April 30, 2024, on Thursday, July 18, 2024, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EST (1:30 P.M. PST). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 135832. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 50895, or by accessing the investors section of the company's website within 72 hours.

全球医学前期和临床研究服务提供商Champions Oncology, Inc. (NASDAQ:CSBR) 将于2024年7月18日星期四的美国股市收盘后公布2024年4月30日止第四季度和全年财务和运营结果,当天将在东部时间下午4:30(太平洋时间下午1:30)举行电话会议讨论结果,请拨打888-506-0062(国内)或973-528-0011(国际),并输入接入代码135832参加。会议的重播可通过拨打877-481-4010(国内)或919-882-2331(国际)并输入密码50895,或在72小时内访问公司网站的投资者部分获得。

About Champions Oncology, Inc.

关于Champions Oncology, Inc。

Champions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative highest-quality data through proprietary in vivo and ex vivo platforms. Through its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical and clinical oncology drug discovery and development programs worldwide. For more information, please visit .

Champions Oncology是一家全球性的临床前和临床研究服务提供商,为生物制药组织提供端到端肿瘤研发解决方案。拥有最大、最详尽的临床相关患者衍生异种移植(PDX)和原发性血液恶性肿瘤模型库,通过专有的体内和体外平台提供创新的高质量数据。通过其大量的尖端生物分析平台、开创性的数据平台和分析,以及科学的卓越性,Champions Oncology推动了全球的临床前和临床肿瘤制药研发计划的进展。有关更多信息,请访问 。

Media Contact:
Rachel Bunting, MS, MBA
VP, Global Marketing
Marketing@ChampionsOncology.com

媒体联系人:
Rachel Bunting, MS, MBA
VP, 全球营销
Marketing@ChampionsOncology.com

SOURCE: Champions Oncology, Inc.

SOURCE:Champions Oncology,Inc。


声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发